Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This is a single-arm phase 2 study to evaluate the preliminary evidence of efficacy and
safety of the combination of acalabrutinib, lenalidomide and rituximab (ALR) in previously
untreated mantle cell lymphoma. The study includes an induction phase consisting of 12 cycles
of ALR. Responding subjects will be eligible to enter a maintenance phase. Subjects will
continue maintenance ALR until disease progression, development of unacceptable toxicity, or
voluntary withdrawal. Subjects will be followed after completing study intervention every 6
months for alternate anti-cancer therapy and survival.